Company: CERO
Filing Date: 2025-05-02
Form Type: PRER14A
Source: 0001213900-25-039149
Chunk: 78

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-02
Form: PRER14A
Chunk 78
---
     |      1,125 | ​(3) |     |            — |      |     | $     |  26,250 | ​(4) |

____________ (1)This includes (i) option to purchase 1,125shares of Common Stock granted to the non -employeedirectors on March 25, 2024 at an exercise price of $177.00 per share, which was reduced to $10.00 effective October 1, 2024 and (ii) option to purchase 2,550 shares of Common Stock, which vested in two equal installments subject to the satisfaction of certain performance criteria; on December 2, 2024, the board of directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 1,275 shares under (ii) and on February 24, 2025, the board of directors confirmed that the performance criteria has been met with regards to the other installment, resulting in the vesting of the remaining 1,275 shares under (ii). (2)This includes the option to purchase 2,550shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria; on December 2, 2024, the board of directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 1,275 shares and on February 24, 2025, the board of directors confirmed that the performance criteria has been met with regards to the other installment, resulting in the vesting of the remaining 1,275 shares under (ii). Mr. Patel received $75,000 in consulting fees pursuant to the agreement between Mr. Patel and the Company.

44 (3)This includes the option to purchase 1,125shares of Common Stock granted to the non -employeedirector on March 25, 2024 at an exercise price of $177.00 per share; such award was forfeited following the director’s resignation from the board of directors. (4)This includes the non -employeedirector compensation for the director for the period of service prior to the director’s resignation from the board of directors. On March 4, 2025, granted to each non -executivedirector options to purchase up to 35,845shares of Common Stock, with 50% subject to vesting on the twelve -monthanniversary of the date of grant and the remaining